156100.KQ L&K Biomed Ltd.

Healthcare Medical Devices KOSDAQ
5,800 KRW
Close of Oct 30, 2026
2,730 16,400
Market cap
KRW 130B
P/E
50.7x
P/B
2.03x
ROE
49.9%
Dividend yield
-
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 156100.KQ undervalued?

Graham number
Price5,800
Graham value2,710
Premium114.0%

156100.KQ trades 114.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

L&K Biomed Ltd. fundamental analysis

8 of 22 checks passed

ROE 2/2

High return on equity (49.9%), above 20%.

ROA 1/1

Return on assets (29.0%) is above the industry median (-9.3%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-249.2%) is below the industry median (-3.8%).

Revenue Growth 2/2

Revenue grew 25.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (0.8%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 11.0x against interest expense, well covered.

PE vs Market 0/1

PE (50.7x) is above the market median (11.3x).

PE vs Industry 0/1

PE (50.7x) is above the industry median (22.5x).

PBV 1/1

Price to book (2.0x) is below the industry median (3.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 103.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

L&K Biomed Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About L&K Biomed Ltd.

L&K Biomed Ltd., engages in the manufacturing, production, and sales of medical devices in South Korea, the United States, Thailand, and internationally. The company offers spinal products comprising BlueEX-T, BluEX-TC, BluEX-A, BlueEX-L, and BluEX-ATP; BluEX-LT, an advanced lateral cage system for spinal lordosis restoration; PathLoc-TM, an expandable TLIF/PLIF lumbar cage system; AccelFix-XL, an expandable lateral lumbar cage system; AccelFix-XTP, an expandable lumbar cage…

Full company profile